Novel (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1. 2016

Petr Šimon, and Ondřej Baszczyňski, and David Šaman, and George Stepan, and Eric Hu, and Eric B Lansdon, and Petr Jansa, and Zlatko Janeba
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, Prague-6 CZ-16610, Czech Republic.

To elucidate the structure-geometry-activity relationship in diarylpyrimidine family (DAPYs) containing carbonyl linker between the central pyrimidine core and phenyl type B-arm, a series of (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones was designed, prepared and tested for their anti-HIV-1 activity. The carbonyl linker bearing B phenyl arm was successfully attached at both C-2 and C-4 positions of the central pyrimidine ring using a new synthetic approach. Further modifications of target compounds are present at C-5 position of the pyrimidine ring. In vitro anti-HIV-1 activity study performed on a series of 22 compounds confirmed the crucial importance of both conformational rigidity between phenyl B arm and the pyrimidine core linked through the carbonyl bridge, as well as presence of fluoro substituents in ortho-positions of phenyl B moiety. The most potent derivative of the series, compound 17, having almost perpendicular angle within the two planes made from the B aromatic arm and the pyrimidine ring, exhibited low nanomolar anti-HIV-1 activity (EC50 = 4 nM) with no significant toxicity (CC50 > 57.1 μM).

UI MeSH Term Description Entries
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse

Related Publications

Petr Šimon, and Ondřej Baszczyňski, and David Šaman, and George Stepan, and Eric Hu, and Eric B Lansdon, and Petr Jansa, and Zlatko Janeba
August 2004, Antiviral research,
Petr Šimon, and Ondřej Baszczyňski, and David Šaman, and George Stepan, and Eric Hu, and Eric B Lansdon, and Petr Jansa, and Zlatko Janeba
January 2022, Molecules (Basel, Switzerland),
Petr Šimon, and Ondřej Baszczyňski, and David Šaman, and George Stepan, and Eric Hu, and Eric B Lansdon, and Petr Jansa, and Zlatko Janeba
June 2015, European journal of medicinal chemistry,
Petr Šimon, and Ondřej Baszczyňski, and David Šaman, and George Stepan, and Eric Hu, and Eric B Lansdon, and Petr Jansa, and Zlatko Janeba
July 2011, Bioorganic & medicinal chemistry,
Petr Šimon, and Ondřej Baszczyňski, and David Šaman, and George Stepan, and Eric Hu, and Eric B Lansdon, and Petr Jansa, and Zlatko Janeba
April 2008, Bioorganic & medicinal chemistry,
Petr Šimon, and Ondřej Baszczyňski, and David Šaman, and George Stepan, and Eric Hu, and Eric B Lansdon, and Petr Jansa, and Zlatko Janeba
February 2019, ACS medicinal chemistry letters,
Petr Šimon, and Ondřej Baszczyňski, and David Šaman, and George Stepan, and Eric Hu, and Eric B Lansdon, and Petr Jansa, and Zlatko Janeba
August 2001, Journal of medicinal chemistry,
Petr Šimon, and Ondřej Baszczyňski, and David Šaman, and George Stepan, and Eric Hu, and Eric B Lansdon, and Petr Jansa, and Zlatko Janeba
October 2019, Molecules (Basel, Switzerland),
Petr Šimon, and Ondřej Baszczyňski, and David Šaman, and George Stepan, and Eric Hu, and Eric B Lansdon, and Petr Jansa, and Zlatko Janeba
February 2004, Journal of medicinal chemistry,
Petr Šimon, and Ondřej Baszczyňski, and David Šaman, and George Stepan, and Eric Hu, and Eric B Lansdon, and Petr Jansa, and Zlatko Janeba
January 2008, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!